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Abstract The source of Parkinson disease-linked a-syn-
uclein (aSyn) in human cerebrospinal ﬂuid (CSF) remains
unknown. We decided to measure the concentration of
aSyn and its gradient in human CSF specimens and com-
pared it with serum to explore its origin. We correlated
aSyn concentrations in CSF versus serum (QaSyn) to the
albumin quotient (Qalbumin) to evaluate its relation to
blood–CSF barrier function. We also compared aSyn with
several other CSF constituents of either central or periph-
eral sources (or both) including albumin, neuron-speciﬁc
enolase, b-trace protein and total protein content. Finally,
we examined whether aSyn is present within the structures
of the choroid plexus (CP). We observed that QaSyn did not
rise or fall with Qalbumin values, a relative measure of
blood–CSF barrier integrity. In our CSF gradient analyses,
aSyn levels decreased slightly from rostral to caudal frac-
tions, in parallel to the recorded changes for neuron-
speciﬁc enolase; the opposite trend was recorded for total
protein, albumin and b-trace protein. The latter showed
higher concentrations in caudal CSF fractions due to the
diffusion-mediated transfer of proteins from blood and
leptomeninges into CSF in the lower regions of the spine.
In postmortem sections of human brain, we detected highly
variable aSyn reactivity within the epithelial cell layer of
CP in patients diagnosed with a range of neurological
diseases; however, in sections of mice that express only
human SNCA alleles (and in those without any Snca gene
expression), we detected no aSyn signal in the epithelial
cells of the CP. We conclude from these complementary
results that despite its higher levels in peripheral blood
products, neurons of the brain and spinal cord represent the
principal source of aSyn in human CSF.
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Introduction
The pathological hallmarks of Parkinson disease (PD)
include progressive cell loss of selective nuclei in the
nervous system and the formation of intracellular aggre-
gates that contain insoluble, wild-type a-synuclein (aSyn)
(Spillantini et al. 1997). The clinical phenotype of auto-
somal dominant PD parallels aSyn gene (SNCA) dosage
with a more severe phenotype observed in the cases of
locus multiplication (Singleton et al. 2003). The quantiﬁ-
cation of the 140 amino acid-long, 16–17 kDa aSyn protein
in biological ﬂuids has been proposed as a biomarker
candidate (Mollenhauer et al. 2010). aSyn has been shown
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DOI 10.1007/s00702-012-0784-0to be present in cerebrospinal ﬂuid (CSF) in low picogram/
microliter amounts; its levels in serum and plasma are up to
tenfold and in whole blood up to 10,000-fold higher
(Mollenhauer et al. 2010) due to the fact that aSyn is also
abundantlyexpressedinthehematopoieticsystem(Scherzer
et al. 2008).
The production and hydrodynamics of human CSF are
complex and vary considerably depending on the level
within the neuroaxis. The three main sources for CSF
constituents comprise: one, the metabolism of neural cells
in the central nervous system (CNS); two, diffusion of
constituents from circulating blood into CSF [even in the
absence of any trauma (Hong et al. 2010; Mollenhauer
et al. 2011)]; and three, the secretion by the epithelial
cells that reside within the brain’s choroid plexus (CP)
(Chodobski and Szmydynger-Chodobska 2001). CSF
volume and its continuous renewal are predominantly
regulated by CP activity. An estimated 80% of all CSF
proteins are blood-derived (with albumin being the most
abundant); their concentrations in the nervous system
increase in the subarachnoid space from rostral to caudal
levels due to diffusion gradients that emanate from blood
vessels intersecting with the ﬂow of CSF (Reiber 2003). A
rise from rostrum to cauda is also observed for certain
constituents that are secreted by leptomeningeal structures
(e.g., b-trace protein) (Reiber 2003) .I nt h ec a s eo f
abnormally low CSF ﬂow rates, which result in increasing
concentrations of blood-derived proteins in lumbar CSF
fractions, the concentration of brain-derived proteins
[e.g., neuronspeciﬁc enolase (NSE)] usually remains
constant (Reiber 2003). Because albumin is solely syn-
thesized in the liver, the quotient of its CSF-to-serum
concentrations (referred to as Qalbumin) reﬂects an indirect
measure of blood–CSF barrier function in vivo.
This study was designed to investigate whether CSF
aSyn is mainly brain or blood derived. To this end, we
compared aSyn concentrations in CSF versus serum
(QaSyn) with Qalbumin in 42 patients with various neuro-
logical diseases. Next, we quantiﬁed aSyn levels in
patients with normal blood–CSF barrier function and
compared them to speciﬁc brain-derived (e.g., NSE),
blood-derived (e.g., albumin), and leptomeninges-derived
(e.g., b-trace) proteins in serially collected CSF samples,
to examine their rostro-caudal concentration gradients.
Furthermore, we also probed whether CP tissue contained
aSyn reactivity.
Methods
We collected CSF and serum from patients with different
neurological conditions. These 42 participants underwent
lumbar puncture (LP) for routine diagnostic purposes
(Table 1) to determine the presence (or absence) of acute
inﬂammatory disease, acute hemorrhage and suspected
Lyme disease (n = 31); to exclude chronic inﬂammatory
diseases (n = 3); to determine carcinomatosis of the lep-
tomeninges in the case of a known primary tumor (n = 4),
and to carry out CSF volume reduction in patients with
normal pressure hydrocephalus (NPH; n = 4). All study
participants were enrolled at the Department of Neurology
at Goettingen University, Germany. Samples were col-
lected and processed as published (Mollenhauer et al.
2010). We further examined samples that featured: a nor-
mal (\5/ll) white blood cell count; the absence of intra-
thecal immunoglobulin production (as determined by the
absence of oligoclonal bands); normal CSF tau protein, and
no LP-induced contamination by blood (determined by a
red blood cell count of\50/ll). CSF aSyn and serum aSyn
(diluted at 1:15) concentrations were measured by enzyme-
linked immunoabsorbent assay (ELISA) as published
(Mollenhauer et al. 2011).
In a second set of study participants we collected CSF
from ﬁve patients at the Paracelsus-Elena-Klinik, Kassel,
Germany. All patients suffered from NPH as determined by
magnetic resonance imaging and according to the estab-
lished clinical criteria (Relkin et al. 2005) (Table 1). We
performed volume reduction by LP on each patient and
serially collected seven CSF fractions (5 ml each) that
were processed as published (Mollenhauer et al. 2010). LP
was carried out at the L2/L3 level in the sitting position,
between 8 and 9 a.m. with the patient having fastened for
12 h. In each fraction we analyzed CSF aSyn (Mollenhauer
et al. 2011), NSE (Schaarschmidt et al. 1994) and b-trace
protein (Tumani et al. 1998), as described. Total protein
and albumin levels were measured by nephelometry (Dade
Behring/Siemens Healthcare Diagnostics).
Immunohistochemistry of postmortem brain sections
containing CP structures was carried out following for-
malin ﬁxation and parafﬁn embedding with anti-aSyn
antibodies, as published (Louis et al. 2005; Schlossmacher
et al. 2002). In parallel, sections from mouse brain trans-
genic for four Ala53Thr-containing human SNCA alleles
(but no mouse Snca) and Snca-null mice without any
endogenous Snca and no transgene expression [engineered
as described (Kuo et al. 2011)] were processed by the same
protocol. Polyclonal (hSA5.1; Open Biosystems Inc) and
Table 1 Demographic data of enrolled patients of both cohorts
Set 1 Set 2
N 42 5
Sex (male/total) 0.5 0.6
Age (years) 58 ± 21 76 ± 4
Mean ± standard deviation (range) (19–93) (69–79)
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123monoclonal (12–1; Epitomics Inc) antibodies to wild-type,
full-length human aSyn were raised in goat and rabbit,
respectively, puriﬁed and characterized (Cullen et al. 2009;
Mollenhauer et al. 2008).
The study was carried out in accordance with the Dec-
laration of Helsinki and with informed written consent
provided by all patients or their next of kin. The study was
approved by the ethics committee at the University of
Goettingen (Germany).
Analysis
Possible correlations between the concentrations of CSF/
serum aSyn to CSF/serum albumin (i.e., Qalbumin) were
analyzed according to Pearson. Results for aSyn, NSE,
b-trace, albumin and total protein values in CSF are
demonstrated in Table 2 and Fig. 1. Statistical analyses
(non-parametric) of the data were performed to assess the
characteristics in CSF vials 5–7 (cisternal fractions) and
1–4 (lumbar fractions) for each described variable using
the trend test from Page (Page 1963). The Page’s L trend
test examined whether the levels are ordered in a speciﬁc
order/sequence. For all tests, the a-level of signiﬁcance was
set at 5 %. Furthermore, effect sizes (Hedge’s g) were
calculated (Ray and Shadish 1996). A correction formula
for small sample bias was also applied (Hedges and Olkin
1985).
Results
CSF a-synuclein in subjects with known blood–CSF
barrier function
CSF specimens analyzed from 42 patients showed a mean
Qalbumin of 8.90 ± 7.7 9 10
-3 (mean ± standard devia-
tion; SD) (range 1.8–37.2 9 10
-3). CSF aSyn levels ran-
ged from 1.29 to 2.97 pg/ll (mean ± SD; 1.99 ± 0.39).
Serum aSyn levels ranged from 14.33 to 67.47 pg/ll (mean
29.54 ± 10.79), and the mean CSF/serum aSyn (QaSyn)
was calculated as 0.08 ± 0.032. The coefﬁcients of
variation (CV) for aSyn values measured 19.6% in CSF,
36.5% in serum, and the CV for QaSyn was 40%. Impor-
tantly, when examining QaSyn together with Qalbumin
values, we recorded no signiﬁcant correlation (-0.109;
p = 0.493; Fig. 2).
CSF a-synuclein and other protein values from
rostro-caudal fractions
CSF aSyn levels across all fractions examined ranged from
1.17 to 2.64 pg/ll (mean 1.70 ± 0.36) in specimens from
ﬁve NPH patients that were analyzed. Qalbumin in these
cases ranged between 5.4 and 7.8 9 10
-3. Across the
35 ml of CSF collected in our NPH patients, aSyn con-
centrations showed a slight increase that initially paralleled
the proximity of the sample collected toward the brain (and
as reﬂected by increasing fraction numbers in the ﬁrst
20 ml collected), which represented a trend without sta-
tistical signiﬁcance (L = 130; p[0.05). The levels of
exclusively neuron-derived NSE remained stable through-
out (L = 134; p[0.05; Table 2; Fig. 1). In contrast,
blood-derived albumin (L = 145.5; p\0.05) and total
protein (L = 139; p\0.05) decrease signiﬁcantly in the
rostral fractions (#5 to #7, i.e., in the last 15 ml of each LP
volume collected; Table 2; Fig. 1) compared to caudal
fractions (#1 to #4, i.e., corresponding to the ﬁrst 20 ml
collected), as expected from the published literature
(Sullivan et al. 2006). Albeit to a lesser extent, leptome-
ninges-derived b-trace protein also showed a mild decrease
in its concentration with progression from the lumbar
region toward the cranial compartment (L = 138.5;
p\0.05). Figure 1 shows the median values for each
fraction and for each protein.
Choroid plexus epithelium is an unlikely source
of a-synuclein
The intra-ventricular network of the CP represents the
predominant site for CSF volume production in vivo. To
also explore CP as a possible source for CSF aSyn, we ﬁrst
examined postmortem human brain sections by routine
Table 2 Quantiﬁcation results
including mean levels in seven
fractions (F1 lower F7 upper
position) for CSF a-synuclein
(aSyn), total protein, albumin,
neuron speciﬁc enolase (NSE)
and b-trace protein
Fractions a-Synuclein
(pg/ll)
Total protein
(mg/l)
Albumin
(mg/l)
NSE
(mg/l)
b-Trace protein
(mg/l)
F7 1.92 387 224 9.49 12.66
F6 1.88 398 226 9.21 12.25
F5 1.91 436 255 9.48 12.86
F4 1.91 449 266 9.30 13.68
F3 1.79 468 290 8.89 14.20
F2 1.69 526 321 9.09 13.94
F1 1.66 634 401 8.41 14.02
Rostrocaudal ratio 1.16 0.61 0.56 1.13 0.90
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123immunohistochemistry (IHC). We unexpectedly detected
highly variable aSyn reactivity within the epithelial cell
layer of human CP (Fig. 3a). When comparing sections
from several diagnostic categories, we saw considerable
differences in the staining intensity of adult CP epithelium
among cases with synucleinopathy [PD, dementia with
Lewy bodies (DLB)], progressive supranuclear palsy,
Alzheimer’s and Huntington disease and aged control
subjects (Fig. 3a; data not shown), but did not record a
correlation between aSyn reactivity in CP epithelium and
the ﬁnal diagnosis. To determine whether the aSyn signal
in postmortem CP was reﬂective of physiological metab-
olism in vivo, we decided to examine brain sections of
‘‘humanized’’ SNCA-transgenic mice (Kuo et al. 2011)
versus animals deﬁcient in murine (and human) aSyn using
the same IHC protocol. There, we detected no aSyn reac-
tivity in the CP epithelium-containing sections of SNCA-
transgenic mice, wild-type animals and Snca-null mice
(Fig. 3b–d; data not shown). In contrast, CNS structures
including neurons and presynaptic terminals (as well as
intravascular erythrocytes) showed strong aSyn immuno-
reactvity, as expected from the corresponding genotype
(Fig. 3b, c; data not shown). We concluded from these
ﬁndings that CP, a highly vascularized organ within the
brain, represents an unlikely source for the constitutive
release of aSyn into CSF in vivo; however, a possible
uptake of aSyn from CSF by CP cells postmortem could not
be excluded.
Discussion
To elucidate the source of aSyn in CSF, we measured its
levels in CSF and serum from a cohort with variable
Qalbumin values (Blennow et al. 1993; Reiber 2003) and in a
second, small cohort of NPH patients, where we measured
rostral caudal
Fig. 1 Median(andinterquartilerange)valuesforCSFtotalprotein(in
mg/dl), albumin (in mg/dl), neuron speciﬁc enolase (NSE) (in mg/l),
b-trace-protein (mg/l) and a-synuclein (aSyn) (in pg/ll 910) in all
seven fractions
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123CSF aSyn together with several proteins from different
CNS sources. Our collective results suggest that CSF aSyn
is predominantly derived from structures and functions
associated with the brain rather than from peripheral blood
products.
CSF aSyn has been discussed as a possible biomarker
for aSyn-related disorders such as PD, DLB and multiple
system atrophy (MSA) (Mollenhauer et al. 2011) and
reviewed in (Mollenhauer et al. 2010); its presence in
normal human CSF has been previously conﬁrmed by mass
spectrometry (Mollenhauer et al. 2008). The majority (but
not all) of the CSF aSyn quantiﬁcation studies conducted
over the last 6 years have shown a decrease of total aSyn
levels in CSF from PD, DLB and MSA patients, as mea-
sured by ELISA and Luminex platforms [reviewed in:
(Mollenhauer et al. 2010, 2011)]. These biomarker explo-
ration efforts raised—among other issues—the question of
the possible sources of CSF aSyn, which theoretically
include the following: (1) physiological exocytosis by
neural cells of the brain and spinal cord (Lee et al. 2005;
Mollenhauer et al. 2008); (2) secretion by the epithelial
cells of the CP; (3) release by cells of the ependymal lining
of the brain’s ventricular system; (4) secretion by endo-
thelial cells of the brain’s vasculature; (5) normal ﬁltration
of peripheral plasma through the brain’s capillary system
(or following a compromise in the integrity of the blood–
CSF barrier); (6) diffusion and/or entry of blood products
in anatomically privileged sites without effective blood–
CSF barrier; and lastly, (7) physiological attrition of neural
cells as well as neuronal injury in the CNS.
Because aSyn is highly abundant in blood cells, espe-
cially in erythrocytes, discrepant ﬁndings across cross-
sectional studies have raised the possibility of divergence
due to artiﬁcial blood contamination, which occurs in
10–20% of routine LPs (Mollenhauer et al. 2010, 2011).
However, in most (but not all) published CSF aSyn quan-
tiﬁcation studies, the possibility of blood contamination as
the source of CSF aSyn has been addressed and largely
excluded [reviewed in (Mollenhauer et al. 2010)].
In examining the inﬂuence of the blood–brain barrier on
CSF and serum aSyn levels from neurological controls, we
found no correlation between the concentration of CSF
aSyn and QaSyn with Qalbumin. Therefore, we concluded that
CSF aSyn levels were not controlled by the blood–CSF
B
C D
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Fig. 3 Probing for a-synuclein (aSyn) reactivity in mammalian
choroid plexus. Formalin-ﬁxed, parafﬁn-embedded sections of post-
mortem human brain are shown, including from a 65-year-old man
with progressive supranuclear palsy (a), and of ‘humanized SNCA’-
transgenic mouse brain (b, c) with a segment of the 4th ventricle
(a, b) or lateral ventricle (c). All sections contain choroid plexus (CP)
epithelium and were probed for aSyn reactivity with anti-aSyn
antibodies by routine immunohistochemistry and counterstained with
hematoxyline. Cortical sections from a Snca-null mouse (d) were
processed in parallel. Antibodies used in a, b and d: goat-anti-human
aSyn (hSA5.1); in c, monoclonal rabbit antibody to human aSyn
(12–1). Representative specimens from human autopsy material
(n = 5), hSNCA
A53T-transgenic mice (n = 4) and Snca-null animals
(n = 2) are shown. Arrows identify unlabelled epithelial cells of CP;
in contrast, stars denote the robust expression of aSyn in the neuropil
of SNCA-expressing mice
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123barrier under physiological conditions. However, larger
cohorts comprising patients with various inﬂammatory
conditions will need to be examined (e.g., multiple scle-
rosis) to discern the effect of aSyn distribution under
pathological blood–CSF barrier conditions.
Due to the protective role of the barrier function on CNS
integrity, we also calculated the coefﬁcients of variation
(CV) as a reﬂection of biological variability. The CV value
for aSyn in CSF was smaller than that for serum aSyn. The
latter observation provided independent (albeit indirect)
support for our conclusion that under normal conditions the
majority of aSyn species detected in CSF was unlikely to
be blood borne; if it would have been predominantly
derived from blood, the CV of CSF aSyn values would
have been expected to be at least equal—if not larger—
than those of serum aSyn. Another possible explanation for
the different CV values is that our assay could have cap-
tured CSF aSyn more readily than serum aSyn (for
example due to protein complex formation and thus altered
antibody accessibility), but this scenario seems unlikely
given the signiﬁcantly larger amounts of aSyn recorded by
our assay in all serum samples than in CSF (Mollenhauer
et al. 2010, 2011).
To further examine aSyn levels along the rostro-caudal
ﬂow of CSF, we collected a total of 35 ml in seven serial
fractions in all NPH patients. The lumbosacral CSF volume
is highly variable among individual patients and is esti-
mated to contain 35.8 ± 10.9 ml with a total range from
10.6 to 61.3 ml in adult humans (Sullivan et al. 2006).
With the LP performed at the L2/L3 level in all study
participants, we inferred that fractions #1–4 contained CSF
from the caudal subarachnoidal space where it supports
spinal cord suspension (and function), whereas fractions
#5–7 represented CSF derived from space closer to (and
above) the craniocervical juncture following direct contact
with the brain. Our analysis revealed the expected rostro-
caudal increase of plasma-derived proteins (i.e., total pro-
tein and albumin), which is thought to reﬂect a longer
transit time of CSF to the lumbar spine region and a higher
proportion of diffusion-mediated transfer of proteins from
blood to CSF (Reiber 2003). In our study, b-trace protein
concentrations also increased in a rostro-caudal gradient,
as expected from studies that simultaneously analyzed
ventricular and lumbar CSF samples (Reiber 2001, 2003);
b-trace protein is mainly released by leptomeningeal
structures. In contrast, the neuron-derived protein NSE
showed the expected rostro-caudal stability in our hands,
possibly even a slight reduction for the concentrations
recorded in lumbar fractions #1–4. These collective ﬁnd-
ings strongly supported the conclusions that these seven
fractions indeed represented different levels of CSF col-
lected from the lumbar as well as cisternal regions of
subarachnoid space. The concentration behavior of our
analyte of interest, total aSyn, behaved most closely to that
of NSE en route from the rostrum of the brain to the
lumbosacral space. This decreasing rostro-caudal gradient
is, therefore, in support of a concept that sees the brain as
the most important source of CSF aSyn followed by ner-
vous system structures below the medulla.
A decreasing rostro-caudal gradient for CSF aSyn con-
centrations was also reported by Hong and colleagues, who
analyzed three fractions in 45 control subjects showing a
trend for decreased CSF aSyn in lower # fractions (Hong
et al. 2010). Although the Hong et al. CSF samples were
not centrifuged after their collection, therefore, raising the
theoretical possibility of blood and epithelial cell contam-
ination (which could have inﬂuenced their ﬁndings), our
results conﬁrm and expand the conclusions reached by
these and other authors exploring the source of extracel-
lular aSyn in human brain (Emmanouilidou et al. 2011).
Our study on CSF aSyn is limited by its small sample
size and a selection bias towards patients with non-neuro-
degenerative conditions. In future studies, patients with
neurodegenerative and inﬂammatory illnesses as well as
medically healthy participants have to be analyzed. Nev-
ertheless, our results support the concept of a source of
CSF aSyn that is predominantly (but not exclusively)
associated with nervous system structure and function
under physiological conditions, and is less likely to be
blood borne. Our results do not exclude the possibility that
this distribution is markedly altered in diseases associated
with signiﬁcant neuronal lysis (e.g., due to prion disease)
(Mollenhauer et al. 2008).
Our ﬁnding of variable immunoreactivities for aSyn
within the epithelium of CP in human brain (but not mouse
brain) sections could indicate a relevant site for aSyn
uptake postmortem from circulating CSF [as reported for
example for amyloid-b-protein (Crossgrove et al. 2005)
(Wolburg and Paulus 2010)] in some patients. However,
our ﬁndings in genetically engineered mice make de novo
gene transcription in CP and secretion (or ﬁltration of aSyn
from plasma into CSF by CP epithelial cells) very unlikely.
Alternatively, technical reasons (such as those related to
possible antibody cross-reactivity with unknown antigens)
when processing human versus mouse brain could also
explain the observed species difference. Lastly, in future
studies we will revisit whether this variable immunoreac-
tivity for aSyn in human CP may be related to the ﬁnal
diagnosis of the patient. To date, we have not yet observed
such a correlation.
Understanding the sources of aSyn, delineating the
molecular events underlying its presumed exocytosis by
cells into the interstitial, ventricular and subarachnoid
spaces of the CNS, and cataloging its modiﬁed variants
represent pivotal tasks for our ﬁeld in the future. They are
important in the identiﬁcation of the unknown function of
744 B. Mollenhauer et al.
123aSyn in CSF, its main degradation pathways in intra- and
extracellular compartments (including in CSF), and its
possible uptake by neural, ependymal and epithelial cells
from circulating CSF. These related topics have major
implications for the pathogenesis, the diagnosis and pos-
sibly, the progression of several, currently incurable syn-
ucleinopathy disorders of the brain including PD, MSA and
DLB (Desplats et al. 2009; Hong et al. 2010; Kramer and
Schulz-Schaeffer 2007; Mollenhauer et al. 2011;Volpicelli-
Daley et al. 2011).
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